Annette Brenner's picture

Annette Brenner

  • E-mailAnnette.Brenner@uib.no
  • Phone+47 469 23 798
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2021). The constitutive extracellular protein release by acute myeloid leukemia cells—A proteomic study of patient heterogeneity and its modulation by mesenchymal stromal cells. Cancers. 25 pages.
  • Show author(s) (2021). Proteomic comparison of bone marrow derived osteoblasts and mesenchymal stem cells. International Journal of Molecular Sciences.
  • Show author(s) (2021). Proteomic Characterization of Spontaneous Stress-Induced In Vitro Apoptosis of Human Acute Myeloid Leukemia Cells; Focus on Patient Heterogeneity and Endoplasmic Reticulum Stress. Hemato. 607-627.
  • Show author(s) (2021). Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells. Diseases.
  • Show author(s) (2021). Longitudinal Study of music Therapy's Effectiveness for Premature infants and their caregivers (LongSTEP): Feasibility study with a Norwegian cohort. The Journal of music therapy. 201-240.
  • Show author(s) (2020). The extracellular bone marrow microenvironment — a proteomic comparison of constitutive protein release by in vitro cultured osteoblasts and mesenchymal stem cells. Cancers.
  • Show author(s) (2019). The capacity of long-term in vitro proliferation of acute myeloid leukemia cells supported only by exogenous cytokines is associated with a patient subset with adverse outcome. Cancers. 1-22.
  • Show author(s) (2019). Proteomic profiling of primary human acute myeloid leukemia cells does not reflect their constitutive release of soluble mediators. Proteomes. 1-10.
  • Show author(s) (2019). High constitutive cytokine release by primary human acute myeloid leukemia cells is associated with a specific intercellular communication phenotype. Journal of Clinical Medicine.
  • Show author(s) (2019). Functional toll-like receptors (TLRs) are expressed by a majority of primary human acute myeloid leukemia cells and inducibility of the TLR signaling pathway is associated with a more favorable phenotype. Cancers.
  • Show author(s) (2019). A kinase inhibitor with anti-Pim kinase activity is a potent and selective cytotoxic agent toward acute myeloid leukemia. Molecular Cancer Therapeutics. 567-578.
  • Show author(s) (2018). Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. Expert opinion on therapeutic targets. 639-653.
  • Show author(s) (2018). Resistance to the antiproliferative in vitro effect of PI3K-Akt-mTOR inhibition in primary human acute myeloid leukemia cells is associated with altered cell metabolism. International Journal of Molecular Sciences. 1-18.
  • Show author(s) (2018). Immunological heterogeneity of healthy peripheral blood stem cell donors - Effects of granulocyte colony-stimulating factor on inflammatory responses. International Journal of Molecular Sciences. 1-16.
  • Show author(s) (2017). The constitutive protease release by primary human acute myeloid leukemia cells. Journal of Cancer Research and Clinical Oncology. 1-14.
  • Show author(s) (2017). Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism. Expert opinion on therapeutic targets. 357-369.
  • Show author(s) (2017). Mesenchymal stem cells support survival and proliferation of primary human acute myeloid leukemia cells through heterogeneous molecular mechanisms. Frontiers in Immunology. 1-17.
  • Show author(s) (2017). CDC25 inhibition in acute myeloid leukemia - A study of patient heterogeneity and the effects of different inhibitors. Molecules. 1-18.
  • Show author(s) (2016). The systemic profile of soluble immune mediators in patients with myelodysplastic syndromes. International Journal of Molecular Sciences.
  • Show author(s) (2016). A subset of patients with acute myeloid leukemia has leukemia cells characterized by chemokine responsiveness and altered expression of transcriptional as well as angiogenic regulators. Frontiers in Immunology.
  • Show author(s) (2015). The importance of sample collection when using single cytokine levels and systemic cytokine profiles as biomarkers - a comparative study of serum versus plasma samples. JIM - Journal of Immunological Methods. 19-28.
  • Show author(s) (2015). The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. Stem Cell Research. 530-541.
  • Show author(s) (2015). Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. OncoTarget. 2794-2811.
  • Show author(s) (2015). Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid. BMC Pharmacology & Toxicology.
  • Show author(s) (2012). Thermal stability of chicken brain alpha-spectrin repeat 17: a spectroscopic study. Journal of Biomolecular NMR. 71-83.
  • Show author(s) (2012). Human Protein N-terminal Acetyltransferase hNaa50p (hNAT5/hSAN) Follows Ordered Sequential Catalytic Mechanism (combined kinetic and NMR study). Journal of Biological Chemistry. 10081-10088.
  • Show author(s) (2005). Characterisation of a prokaryotic hemerythrin from the methanotrophic bacterium Methylococcus capsulatus (Bath). The FEBS Journal. 2428-2440.
  • Show author(s) (2019). Exploring the Bruserud-Brenner axis in acute myeloid leukaemia.
  • Show author(s) (2018). Long-term suspension culture of AML blasts - increased number of clonogenic cells as an adverse prognostic factor .
  • Show author(s) (2015). Mesenchymal stem cells in co-culture with primary AML cells.
Academic lecture
  • Show author(s) (2020). LongSTEP: Implementering av en internasjonal klinisk studie om musikkterapi for premature barn og deres foreldre .
  • Show author(s) (2019). Music therapy for people with substance use disorders: preliminary findings from a Cochrane systematic review.
  • Show author(s) (2015). CDC25 inhibition in AML.
  • Show author(s) (2012). Intermolecular interactions of bioorganic molecules studied by liquid state NMR spectroscopy.
  • Show author(s) (2012). Biomolecular NMR spectrocopy and its applications.
  • Show author(s) (2010). Backbone assignment strategy for two medium-sized proteins.
Short communication
  • Show author(s) (2020). Music therapy for people with substance use disorders (Protocol). Cochrane Database of Systematic Reviews.
  • Show author(s) (2014). Using MUSIC and CC(CO)NH for Backbone Assignment of Two Medium-Sized Proteins Not Fully Accessible to Standard 3D NMR. Molecules. 8890-8903.
Masters thesis
  • Show author(s) (2006). The haemerythrin of Methylococcus capsulatus ( Bath ); a structutal study using physical-chemical methods.
Letter to the editor
  • Show author(s) (2017). Rethinking the role of osteopontin in human acute myeloid leukemia. Leukemia and Lymphoma. 1494-1497.
Doctoral dissertation
  • Show author(s) (2012). Revealing the secrets of proteins – a triple-nuclear and multi-dimensional high-resolution NMR study.
  • Show author(s) (2021). Genetic profiling and the diagnostic challenge of rare paediatric hepatic tumours .
  • Show author(s) (2012). Investigation of the human protein Nα-acetyltransferase hNaa50p enzyme mechanism by heteronuclear NMR spectroscopy.
Academic literature review
  • Show author(s) (2022). Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia. Molecules.
  • Show author(s) (2021). Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma—A Comprehensive Update. Pharmaceutics. 1427.
  • Show author(s) (2018). The possible importance of β3 integrins for leukemogenesis and chemoresistance in acute myeloid leukemia. International Journal of Molecular Sciences. 1-17.
  • Show author(s) (2018). S100 proteins in acute myeloid leukemia. Neoplasia. 1175-1186.
  • Show author(s) (2016). The complexity of targeting PI3K-Akt-mTOR signalling in human acute myeloid leukaemia: The importance of leukemic cell heterogeneity, neighbouring mesenchymal stem cells and immunocompetent cells. Molecules. 32 pages.
  • Show author(s) (2015). Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication. Expert Review of Hematology. 299-313.
  • Show author(s) (2014). Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid Leukemia - The possibility to target several kinases through inhibition of the various CDC25 isoforms. Molecules. 18414-18447.
  • Show author(s) (2014). Heat shock protein 90 – a potential target in the treatment of human acute myelogenous leukemia. Advances in cancer drug targets. 3-53.
  • Show author(s) (2014). Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia? Expert opinion on therapeutic targets. 929-944.

More information in national current research information system (CRIStin)